Basilea opens new phase III study in special patient populations for its broad-spectrum antifungal isavuconazole
Basilea Pharmaceutica Ltd. announced that it has opened an additional phase III study to evaluate the efficacy and safety of isavuconazole in treating serious and life-threatening invasive fungal infections. Isavuconazole's breadth of spectrum in vitro and its favorable pharmacokinetic profile formed the basis of this open label study.
Basilea is currently conducting pivotal randomized phase III studies focusing on first-line treatment against invasive aspergillus or candida bloodstream infections. This additional supportive international multicenter safety and efficacy study will include aspergillosis patients with impaired renal function and patients with rare mold infections. The study is expected to provide additional confirmation of the potential advantages of intravenous and oral isavuconazole over existing antifungals in terms of consistently effective drug levels, convenience, and clinical safety. These data are intended to complement the planned regulatory package.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Aphton to Expand Licensing and Commercialization Agreements Into Europe for two Antibodies

3D IR images now in full color - Berkeley Lab and University of Wisconsin researchers unveil FTIR spectro-microtomography
Predicting the spread of microbes in spacecraft - Also methods for managing infection risks in public transport, hospitals and offices
Category:Animal_diseases
BioTek Instruments Announces Establishment of Korean Office
Almirall completes deal with AstraZeneca in respiratory disease
